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ABSTRACT
Purpose: To evaluate short- and long-term efficacy and safety of ixekizumab in patients according to
psoriasis severity.
Materials and methods: Data were integrated from clinical trials (UNCOVER-2, UNCOVER-3). Patients
received placebo, 80-mg ixekizumab every 2weeks (IXEQ2W), every 4weeks (IXEQ4W), or 50mg etaner-
cept (ETN) biweekly for 12weeks, then open-label IXEQ4W (UNCOVER-3). Psoriasis severity was categorized
by baseline Psoriasis Area and Severity Index (PASI<20 and 20). Efficacy was evaluated by percentage
reaching PASI 75, 90, 100, and absolute PASI5, 2, and 1.
Results: Significantly more patients with PASI20 (vs. PASI<20) were male and had higher body weight.
After 12weeks, both severity groups had significantly more IXEQ2W- than ETN-treated patients reach PASI
75, 90, 100, and absolute PASI5, 2, 1. Fewer PASI20 vs. PASI<20 patients across treatments
reached PASI5, 2, and 1 at week 12. Efficacy was maintained during 156weeks of ixekizumab treat-
ment with no differences between groups. The IXEQ2W safety profile was similar between groups except
for injection-site reactions (significantly higher in PASI<20).
Conclusions: Ixekizumab demonstrated a high level of efficacy and had a consistent safety profile in
patients with different baseline psoriasis severity levels.
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Introduction
Ixekizumab is an interleukin (IL)-17A antagonist that has been
studied in three randomized, double-blind, placebo-controlled
phase 3 trials (UNCOVER-1, UNCOVER-2, and UNCOVER-3). In these
studies, ixekizumab was reported to have high efficacy in patients
with moderate-to-severe plaque psoriasis (1,2).
The Psoriasis Area and Severity Index (PASI) score, in use since
1978, is the most prevalent measure of psoriasis severity in clinical
trials (3,4). A PASI total score 7–12 was introduced to define mod-
erate and 12 to define severe psoriasis (3,4). Some studies have
demonstrated the need to further differentiate patients with
higher levels of severity, proposing an additional threshold of total
PASI score (5). For example, National Institute for Health and
Clinical Excellence guidelines currently define psoriasis as very
severe when patients present with PASI total score 20 and
Dermatology Life Quality Index (DLQI) total score >18 and
European Medicines Agency guidelines define psoriasis as severe
when patients present with PASI total score>20 or body surface
area involvement>20% (6,7).
There is very limited information on whether the efficacy of
biologic therapies is impacted by baseline psoriasis severity as
these analyses are rarely reported in clinical trials or registries. In a
retrospective analysis of patients evaluated at two clinical centers,
Ponnambath et al. (8) observed that within the group of patients
with PASI>20, those who were taking etanercept (ETN)
discontinued their therapy more often than those treated with
other biologics, and hypothesized that this could be related to
lower efficacy of ETN in this population. In another report, 6- and
12-month analyses of biologic agents used to treat psoriasis in a
real-world setting showed that patients with more severe baseline
disease were less likely to achieve clear to minimal disease targets
as measured by the Physician Global Assessment Scale (9).
The objective of this post hoc analysis was to compare the
short- and long-term efficacy and safety of ixekizumab, used
according to the approved labeling, in patients with varying
degrees of psoriasis severity (defined by baseline PASI total
score<20 [PASI<20] and PASI total score20 [PASI20]) by
using integrated data from two active comparator- and placebo-
controlled trials, UNCOVER-2 and UNCOVER-3.
Materials and methods
Study design
Data presented are based on integrated data from two phase 3,
multicenter, randomized, double-blind, placebo-controlled, paral-
lel-group trials that evaluated the efficacy and safety of
ixekizumab (UNCOVER-2 [NCT01597245] and UNCOVER-3
[NCT01646177]). The designs of UNCOVER-2 and UNCOVER-3 have
been previously described (1,2). Briefly, the UNCOVER-2 and
UNCOVER-3 studies had a 12-week placebo-controlled induction
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dosing period where patients were randomized to receive pla-
cebo, 80mg ixekizumab every 2weeks (IXEQ2W), 80mg ixekizu-
mab every 4weeks (IXEQ4W), or an active comparator, etanercept
(ETN; 50mg twice weekly). UNCOVER-2 had a randomized with-
drawal period from Week 12 to Week 60 where patients who had
reached static Physician Global Assessment (sPGA) 0 or 1 at Week
12 were re-randomized to receive IXEQ4W, 80mg ixekizumab
every 12weeks (IXEQ12W), or placebo (UNCOVER-2 data beyond
Week 12 are not included in this report). In UNCOVER-3, after
Week 12, all patients entered a long-term extension period, during
which they received open-label IXEQ4W through Week 264
regardless of their treatment before Week 12. In addition, after
Week 60 of the UNCOVER-3 study, at the investigator’s discretion,
the dosing frequency could be increased to IXEQ2W for the
remainder of the study to maintain disease control. For the pur-
pose of this report, only UNCOVER-3 data are used for analyses
beyond Week 12; data from visits where the ixekizumab dose was
up-titrated to IXEQ2W were excluded from efficacy analyses, but
not safety analyses.
Patients
Detailed inclusion and exclusion criteria have been previously
reported (1,2). In both studies, eligible patients were at least
18 years of age with chronic (6months) moderate-to-severe
psoriasis (10% body surface area involvement, sPGA score3,
and PASI total score12 at baseline) and were candidates for
phototherapy and/or systemic therapy. Study protocols and
informed consent forms were approved by an investigational
review board at each site. The studies were conducted in accord-
ance with ethical principles of Good Clinical Practice and the
Declaration of Helsinki and its guidelines. Written informed con-
sent was obtained from each patient at study entry before any
study procedures as previously described (2).
Assessments
Demographics and disease characteristics, including psoriasis
severity measured by PASI, were assessed at baseline.
Short-term (12-week) and long-term (up to 156weeks [3 years])
efficacy was evaluated by the number (%) of patients with reduc-
tion from baseline PASI of at least 75% (PASI 75), at least 90%
(PASI 90), and 100% (PASI 100) as well as the number (%) of
patients achieving an absolute (total score) PASI5, 2, and 1.
Safety was evaluated by the incidence of treatment-emergent
adverse events (TEAEs) and serious adverse events (SAEs) reported
over 12weeks and 156weeks (3 years) of ixekizumab treatment.
AEs of special interest included, but were not limited to, infec-
tions, inflammatory bowel disease, injection-site reactions, and
cardiovascular and cerebrovascular events.
Statistical analyses
Short-term analyses used baseline efficacy and safety data from
the UNCOVER-2 and UNCOVER-3 studies and long-term analyses
used efficacy and safety data from the UNCOVER-3 study only.
Baseline, efficacy, and safety data in the overall population have
already been reported (1,2,10,11). For the current analyses,
patients were grouped by baseline psoriasis severity (PASI<20
and PASI20).
For demographic and baseline variables, p values for the differ-
ence between psoriasis severity groups were analyzed using the
Cochran–Mantel–Haenszel (CMH) test stratified by study for
categorical data and an analysis of variance with treatment, study,
and severity group as independent factors for continuous data.
For short-term analyses (up to Week 12) of categorical efficacy
variables (i.e. PASI 75, PASI 90, and PASI 100; PASI5, PASI2,
and PASI1), a logistic regression analysis was used with treat-
ment, subgroup, and the interaction of treatment-by-subgroup
included as factors, and the treatment-by-subgroup interaction.
For the within subgroup between treatment comparisons, 95%
confidence intervals [CIs] were based on the normal approxima-
tion to the binomial distribution. p values from the CMH test
stratified by study was used. For the binary PASI outcomes, miss-
ing data were imputed using a non-responder imputation (NRI)
up to Week 12.
For analyses beyond 12weeks, only data from visits with treat-
ment at the approved IXEQ4W regimen were considered. Data col-
lected after the first visit with an up-titrated IXEQ2W long-term
dosing were excluded before imputations were applied. For binary
PASI outcomes, missing data were imputed using a modified NRI
(mNRI) for data in the long-term analyses. For the mNRI, the NRI
method was used for patients who discontinued due to adverse
events or lack of efficacy/relapse; in all other cases of missing data
for this analysis, the data were imputed using a partial imputation
of non-monotone missing data (i.e. for intermittent missing data)
using the Markov chain Monte Carlo method with the simple
imputation model, and then for the monotone missing data, a
sequential regression multiple imputation with the baseline
score (12,13).
For adverse event data, p values for the difference between
psoriasis severity groups were calculated using the CMH
test stratified by study for data up to Week 12. For all analyses,
p values .05 indicated statistical significance and no correction
for multiplicity was applied due to the exploratory nature of
the analyses.
For the absolute PASI response animation, a cubic Bezier inter-
polation was used to interpolate (for non-scheduled time points)
through observations over time for each patient. Observations at
each visit were obtained, and if any data were missing at a sched-
uled visit, it was imputed using the last observation carried for-
ward method. In the animation, each patient is represented by a
dot; the dot color is associated with PASI change from baseline.
For each arm, a stacked bar chart (upper left of figures in anima-
tion) presents the distribution of patients by baseline PASI.
Results
A total of 2570 patients were enrolled and randomized in the
UNCOVER-2 and UNCOVER-3 studies (2). Of these patients, 1590
(61.9%) had baseline PASI<20 and 977 (38.0%) had baseline
PASI20. The remaining three patients had missing baseline PASI
values and were not included in this analysis. The distributions of
baseline PASI scores are shown in Supplemental Figure 1. A total
of 362 patients who received IXEQ2W during the 12-week induc-
tion entered the long-term extension of UNCOVER-3 and received
open-label IXEQ4W. Between Week 60 and Week 156, 55 of the
362 patients (15.2%) were up-titrated to IXEQ2W (data from visits
where the ixekizumab dosing was up-titrated were excluded from
efficacy analyses).
Baseline patient demographics and clinical characteristics by
baseline psoriasis severity are reported in Table 1. Several baseline
variables were statistically significantly different between the psor-
iasis severity groups. Patients with more severe psoriasis
(PASI20) were more frequently male (71.3% vs. 65.3%), from
Europe (53.5% vs. 36.5%), and had a higher mean body weight
(93.7 kg vs. 89.9 kg) compared to patients with less severe
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psoriasis (PASI<20). More patients with baseline PASI20 than
those with PASI<20 reported previous treatments with non-bio-
logic systemic drugs (58.2% vs. 49.3%), but not with biologics
(17.3% vs. 20.6%). Patients with baseline PASI20 also had a
higher prevalence of nail (67.0% vs. 58.1%), face (51.1% vs. 39.9%),
and palm/sole (30.4% vs. 24.6%) involvement, a higher frequency
of psoriatic arthritis (27.0% vs. 18.7%), and a worse mean baseline
DLQI score (13.5 vs. 11.3) than those with PASI<20.
Short-term (12-week) efficacy
The animation (Supplemental Figure 2) presents the evolution of
PASI scores (LOCF) through the induction phase of UNCOVER-2
and -3 for all randomized patients treated with IXEQ2W and ETN,
as well as the distribution of the percentages of patients reaching
PASI 50, PASI 75, PASI 90, and PASI 100 among the PASI<20 and
the PASI20 groups.
At 12weeks, there was no meaningful impact of baseline psor-
iasis severity on the efficacy of IXEQ2W as the percentage of
patients reaching PASI 75, PASI 90, and PASI 100 at Week 12 were
similar in patients with baseline PASI>20 and patients with base-
line PASI<20, respectively (Figure 1, NRI). A significantly higher
percentage of IXEQ2W-treated patients than ETN-treated patients
reached PASI 75 (236 [90.4%] vs. 131 [49.6%] patients, p< .001),
PASI 90 (196 [75.1%] vs. 75 [28.4%] patients, p< .001), and PASI
100 (101 [38.7%] vs. 20 [7.6%] patients, p< .001) in the PASI20
group (Figure 1, NRI). Similarly, a significantly higher percentage
of IXEQ2W- than ETN-treated patients reached PASI 75 (415
[87.4%] vs. 222 [46.6%] patients, p< .001), PASI 90 (314 [66.1%] vs.
90 [18.9%] patients, p< .001), and PASI 100 (186 [39.2%] vs. 27
[5.7%] patients, p< .001) in the PASI<20 group (Figure 1, NRI).
Table 1. Baseline patient demographics and clinical characteristics by baseline psoriasis severity.
PASI<20 (N¼ 1590) PASI 20 (N¼ 977) Total (N¼ 2567) p value
Gender .002
Male, n (%) 1039 (65.3) 697 (71.3) 1736 (67.6)
Female, n (%) 551 (34.7) 280 (28.7) 831 (32.4)
Geographic region, n (%) <.001
Europe 580 (36.5) 523 (53.5) 1103 (43.0)
North America 930 (58.5) 381 (39.0) 1311 (51.1)
Weight (kg), mean (SD) 89.9 (22.4) 93.7 (23.5) 91.4 (22.9) <.001
Age at enrollment (years), mean (SD) 45.5 (13.2) 45.1 (12.9) 45.4 (13.1) .393
Age at psoriasis onset (years), mean (SD) 27.3 (14.6) 27.6 (14.0) 27.4 (14.4) .659
Duration of psoriasis (years), mean (SD) 18.7 (12.7) 17.9 (11.6) 18.4 (12.3) .148
Previous use of non-biologic systemic therapy, n (%) 784 (49.3) 569 (58.2) 1353 (52.7) <.001
Previous use of biologic systemic therapy, n (%) 328 (20.6) 169 (17.3) 497 (19.4) .082
Nail psoriasis, n (%) 924 (58.1) 655 (67.0) 1579 (61.5) <.001
Facial psoriasis, n (%) 634 (39.9) 499 (51.1) 1133 (44.2) <.001
Palmoplantar psoriasis, n (%) 391 (24.6) 297 (30.4) 688 (26.8) <.001
Medical history of psoriatic arthritis, n (%) 298 (18.7) 264 (27.0) 562 (21.9) <.001
Baseline DLQI, mean (SD) 11.3 (6.5) 13.5 (7.4) 12.2 (6.9) <.001
DLQI: Dermatology Quality of Life Index; N: total number of patients; PASI: Psoriasis Area and Severity Index; SD: standard deviation.
p values .05 are bolded.
p values are based on Cochran–Mantel–Haenszel test stratified by study for categorical data and analysis of variance for continuous data with
treatment and study as independent factors.
Figure 1. PASI 75, PASI 90, and PASI 100 response at week 12 for patients administered IXEQ2W or ETN by baseline psoriasis severity (NRI). ETN: etanercept; IXEQ2W:
ixekizumab 80mg every 2weeks; N: total number of patients; NRI: non-responder imputation; PASI: Psoriasis Area and Severity Index. p< .001, IXEQ2W vs. ETN.
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There were no statistically significant interactions between base-
line PASI score and treatment.
In the case of high baseline PASI values, patients with PASI
75 may still present with significant disease. For this reason, we
also evaluated efficacy data in terms of absolute PASI values and
observed, again, limited impact of baseline severity on the effi-
cacy of IXEQ2W. By Week 12, a significantly higher percentage
of IXEQ2W-treated patients than ETN-treated patients reached
PASI5 (227 [87.0%] vs. 109 [41.3%] patients, p< .001), PASI2
(175 [67.0%] vs. 64 [24.2%] patients, p< .001) and PASI1 (132
[50.6%] vs. 36 [13.6%] patients, p< .001) in the PASI20 group
(Figure 2, NRI). Similarly, a significantly higher percentage of
IXEQ2W- than ETN-treated patients reached PASI5 (430 [90.5%]
vs. 266 [55.9%] patients, p< .001), PASI2 (352 [74.1%] vs. 123
[25.8%] patients, p< .001), and PASI1 (270 [56.8%] vs. 63
[13.2%] patients, p< .001) in the PASI<20 group (Figure 2, NRI).
Of note, a slightly lower percentage of patients with PASI20
than with PASI<20 reached PASI<5, <2, and <1 at Week 12.
There were no statistically significant interactions between base-
line PASI score and treatment. The animation shows the com-
parative dynamic of PASI improvement between treatment
groups and across different baseline disease severity
(Supplemental Figure 2).
Long-term (156-week) efficacy
As shown in Figure 3, a high level of efficacy was maintained with
IXEQ2W/IXEQ4W over 156weeks of treatment in both baseline
psoriasis severity groups. PASI 75 (mNRI) was reached by 90.2%
and 89.1% of ixekizumab-treated patients in the PASI20 and
<20 groups, respectively, at Week 52, by 84.7% and 83.1% of
patients at Week 108, and by 81.7% and 79.6% at Week 156. PASI
90 (mNRI) was reached by 81.7% and 76.7% of ixekizumab-treated
patients in the PASI20 and<20 groups, respectively, at Week
52, by 69.7% and 69.2% at Week 108, and by 65.1% and 66.6% at
Week 156. PASI 100 (mNRI) was reached by 59.4% and 54.1% of
ixekizumab-treated patients in the PASI20 and <20 groups,
respectively, at Week 52, by 49.5% and 47.4% of patients at Week
108, and by 46.0% and 44.4% of patients at Week 156. PASI
improvement results based on observed data were better than
the corresponding mNRI results. For instance, PASI 75 (observed)
was reached by 95.1% and 94.9% of ixekizumab-treated patients
in the PASI20 and <20 groups, respectively, at Week 52, by
93.0% and 94.9% of patients at Week 108, and by 99.0% and
95.9% at Week 156 (Figure 3(A)). Consistent with the PASI 75 data,
the pattern of results based on observed data for PASI 90 and
PASI 100 was also better than the corresponding mNRI data
(Figure 3(B,C)).
For analyses of absolute PASI, a consistent pattern of efficacy
was also observed between the two groups of patients. Among
IXEQ2W/IXEQ4W-treated patients, PASI5 (mNRI) was reached by
86.3% in the PASI20 group and 90.3% in the PASI<20 group at
Week 52, by 80.9% and 84.7% at Week 108, and by 76.3% and
82.6% at Week 156 (Figure 4(A)). A PASI2 (mNRI) was reached
by 77.6% in the PASI20 group and 80.7% in the PASI<20 group
at Week 52, by 68.0% and 73.1% at Week 108, and by 63.8% and
71.0% at Week 156 (Figure 4(B)). Among IXEQ2W/IXEQ4W-treated
patients, 70.8% in the PASI20 group and 70.4% in the PASI<20
group achieved PASI1 (mNRI) at Week 52, while 59.8% and
63.1% reached PASI1 at Week 108, and 56.8% and 61.0% at
Week 156 (Figure 4(C)). Absolute PASI results based on observed
data were better than the corresponding mNRI results. For
instance, PASI5 (observed) was reached by 90.8% in the
PASI20 group and 96.0% in the PASI<20 group at Week 52, by
89.8% and 96.6% at Week 108, and by 96.0% and 98.6% at Week
156 (Figure 4(A)). Consistent with the absolute PASI5 data, the
pattern of results based on observed data for absolute PASI2
and PASI1 was also better than the corresponding mNRI data
(Figure 4(B,C)).
A similar pattern of results was observed for PASI improvement
and absolute PASI data among patients in the PASI20 and
PASI<20 groups who switched to IXEQ4W after receiving ETN in
the first 12weeks of the study (data not shown).
Figure 2. Absolute PASI5, PASI2, and PASI1 by baseline psoriasis severity at Week 12 (NRI). ETN: etanercept; IXEQ2W: ixekizumab 80mg every 2weeks; N: total
number of patients; NRI: non-responder imputation; PASI: Psoriasis Area and Severity Index. p< .001, IXEQ2W vs. ETN.
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Short-term (12-week) safety
The frequency of TEAEs and SAEs through Week 12 by group of
psoriasis severity are presented in Table 2. At Week 12, in general,
the safety profile of IXEQ2W was comparable between patients
with baseline PASI20 and PASI<20. The frequencies of SAEs
were similar in the IXEQ2W and ETN treatment arms, while SAEs
were significantly higher in the placebo arm for patients with
PASI20 compared to those with PASI<20 (4.7% vs. 0.5%;
p¼ .009). In addition, in all treatment arms, the frequency of injec-
tion-site reactions was significantly higher in the patients with
baseline PASI <20 than in those with PASI20 (placebo: 5.7% vs.
0.7%, p¼ .012; IXEQ2W: 19.7% vs. 13.4%, p¼ .050; ETN: 19.8% vs.
10.6%, p¼ .002).
Long-term (3-year) safety
Rates of TEAEs and SAEs over 156weeks by psoriasis severity are
presented in Table 3. Similar to the 12-week induction period, the
frequencies of TEAEs and SAEs remained generally consistent for
patients in the PASI20 and PASI<20 groups. Two deaths were
reported in the IXEQ2W/IXEQ4W group. A lower percentage of
patients with baseline PASI20 than in those with PASI<20 dis-
continued due to TEAEs in the IXEQ2W/IXEQ4W treatment group.
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Figure 3. PASI 75, PASI 90, and PASI 100 response by baseline psoriasis severity
at Week 156 (mNRI and observed). (A) PASI 75 over 156weeks of treatment.
Some values are obscured where data overlap for the two observed groups.
(B) PASI 90 over 156weeks of treatment. (C) PASI 100 over 156weeks of treat-
ment. Abbreviations: IXEQ2W: ixekizumab 80mg every 2weeks; mNRI: modified
non-responder imputation; N: total number of patients; PASI: Psoriasis Area and
Severity Index; Q4W: every 4weeks.
Figure 4. Absolute PASI5, PASI2, and PASI1 by baseline psoriasis severity
at Week 156 (mNRI and observed). (A) PASI5 over 156weeks of treatment. (B)
PASI2 over 156weeks of treatment. (C) PASI1 over 156weeks of treatment.
Abbreviations: IXEQ2W: ixekizumab 80mg every 2weeks; mNRI: modified non-
responder imputation; N: total number of patients; PASI: Psoriasis Area and
Severity Index; Q4W: every 4weeks.
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The frequency of injection-site reactions remained lower in the
PASI20 than the PASI<20 group, although in general, these
rates decreased from the Week 12 rates in the IXEQ2W/IXEQ4W
group. The frequency of cerebrovascular/cardiovascular events
was numerically lower in the PASI<20 group than the
PASI20 group.
Discussion
There is very limited data on the potential impact of baseline
psoriasis severity on the efficacy and safety of biologic therapies.
In this report, we compared for the first time the long-term effi-
cacy and safety of ixekizumab in patients with baseline
PASI<20 and20.
Patients with more severe psoriasis (PASI20) were character-
ized by higher mean body weight, were more frequently male,
had higher prevalence of nail, face, palm, and sole involvement,
were more frequently from Europe, had more frequent prior treat-
ment with non-biologic systemic drugs, had higher frequency of
psoriatic arthritis, and had a higher baseline DLQI score.
Consistent with the findings of this study, differences in psoriasis
severity have been reported between men and women (14,15) as
well as patients with facial involvement versus those without
(16,17). The higher prevalence of European patients in the group
of baseline PASI20 may reflect differences of practice
between Europe and North America, with later use of biologics in
Europe (also reflected by the more frequent exposure to conven-
tional systemic drugs in this population) (18).
Superior efficacy of ixekizumab over placebo and ETN has
been reported previously (1,2). The additional analyses presented
here show the consistent response with ixekizumab treatment
across differing disease severities and over time (with up to
Table 3. Week 12–156 rates of treatment-emergent adverse events and serious adverse events by
baseline psoriasis severity.
IXEQ2W/IXEQ4W (N¼ 362)
PASI<20 (N¼ 214) n (%) PASI 20 (N¼ 148) n (%)
Discontinuation due to AE 15 (7.0) 8 (5.4)
Any serious AE 21 (9.8) 18 (12.2)
Death 1 (0.5) 1 (0.7)
Any TEAE 191 (89.3) 127 (85.8)
AEs of special interest
Allergic reaction/hypersensitivity 29 (13.6) 18 (12.2)
Cytopenia – SOC 6 (2.8) 5 (3.4)
Depression 5 (2.3) 3 (2.0)
Hepatic event 15 (7.0) 12 (8.1)
CCE 4 (1.9) 5 (3.4)
IBDa 0 1 (0.7)
Infection 150 (70.1) 99 (66.9)
Injection-site reactions 20 (9.3) 11 (7.4)
Interstitial lung disease 0 0
Malignancies 4 (1.9) 1 (0.7)
AE: adverse event; CCE: cerebro-cardiovascular events; IBD: inflammatory bowel diseases; IXEQ2W: ixe-
kizumab 80mg every 2weeks; IXEQ4W: ixekizumab 80mg every 4weeks; N: total number of patients;
PASI: Psoriasis Area and Severity Index; SOC: system organ class.
aIncludes Crohn’s disease and ulcerative colitis.
Table 2. Week 12 rates of treatment-emergent adverse events and serious adverse events by baseline psoriasis severity.
PBO ETN IXEQ2W


















n (%) p valueb
Discontinuation due to AE 1 (0.5) 2 (1.3) .389 6 (1.3) 3 (1.1) .908 9 (1.9) 6 (2.3) .767
Any serious AE 1 (0.5) 7 (4.7) .009 9 (1.9) 6 (2.3) .702 7 (1.5) 7 (2.7) .300
Death 0 0 – 0 0 – 0 0 –
Any TEAE 100 (47.6) 62 (41.3) .283 265 (55.8) 138 (52.3) .475 281 (59.4) 143 (54.8) .314
AEs of special interest
Allergic reaction/hypersensitivity 4 (1.9) 3 (2.0) .955 13 (2.7) 6 (2.3) .782 20 (4.2) 8 (3.1) .469
Cytopenia – SOC 1 (0.5) 2 (1.3) .362 5 (1.1) 6 (2.3) .194 4 (0.8) 4 (1.5) .334
Depression 0 2 (1.3) .093 4 (0.8) 3 (1.1) .614 2 (0.4) 1 (0.4) .994
Hepatic event 0 1 (0.7) .255 9 (1.9) 8 (3.0) .349 10 (2.1) 4 (1.5) .553
CCE 0 1 (0.7) .255 1 (0.2) 1 (0.4) .576 2 (0.4) 1 (0.4) .892
IBDa 0 0 – 0 0 – 1 (0.2) 1 (0.4) .662
Infection 44 (21.0) 30 (20.0) .922 110 (23.2) 51 (19.3) .367 132 (27.9) 58 (22.2) .158
Injection-site reactions 12 (5.7) 1 (0.7) .012 94 (19.8) 28 (10.6) .002 93 (19.7) 35 (13.4) .050
Interstitial lung disease 0 0 – 0 0 – 1 (0.2) 0 .408
Malignancies 0 0 – 1 (0.2) 0 .496 3 (0.6) 0 .255
AE: adverse event; CCE: cerebro-cardiovascular events; ETN: etanercept; IBD: inflammatory bowel diseases; IXEQ2W: ixekizumab 80mg every 2weeks; N: total number
of patients; PASI: Psoriasis Area and Severity Index; PBO: placebo; SOC: system organ class.
p values .05 are bolded.
aIncludes Crohn’s disease and ulcerative colitis.
bComparison between psoriasis severity groups using Cochran–Mantel–Haenszel test stratified by study.
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156weeks of treatment). Consistency across severity groups was
observed not only for PASI improvement, but more importantly,
for absolute PASI data as well, with comparable percentage of
patients reaching a high level of clearance (PASI2 and PASI1).
The efficacy of ETN was also quite consistent across psoriasis
severity groups in this study, although data were only collected
out to 12weeks for the ETN treatment arm. Of note, more patients
with PASI20 than PASI<20 achieved relative improvements in
PASI (i.e. PASI 75 and 90), whereas the reverse was observed for
absolute PASI (i.e. PASI5,2, and1). For patients with higher
baseline PASI scores, the changes in the individual components of
the PASI may be more dramatic, making it easier for them to
achieve relative improvements in PASI. Thus, absolute PASI data
should also be taken into consideration when determining the
improvements patients may achieve with treatment.
Overall, with long-term ixekizumab treatment (up to
156weeks), patients demonstrated a high level of efficacy that
was maintained across patients with different baseline psoria-
sis severity.
The safety profile of ixekizumab in patients with moderate-to-
severe plaque psoriasis was comparable to that previously
reported (1,2,11,19,20). Discontinuation rates were2% and were
not significantly different between severity groups. The incidence
of cerebro-cardiovascular events was higher among patients with
more severe disease, which is consistent with severe psoriasis
being a known risk factor for cardiovascular events (21,22). Of
note, the incidence of injection-site reactions was consistently
lower in patients with more severe disease across treatment arms.
All other adverse events were comparable between the baseline
psoriasis severity groups.
Limitations
Some limitations to this analysis should be considered. First, all
analyses within this report are post hoc analyses. In addition, the
active comparator, ETN, was only evaluated out to 12weeks and
the long-term treatment period was open-label.
Conclusions
Overall, ixekizumab provided a high level of response with a
favorable safety profile to patients with moderate-to-severe pla-
que psoriasis independent of baseline PASI severity level. Notably,
patients with more severe psoriasis (PASI20) were more fre-
quently characterized by certain traits, such as higher mean body
weight and higher prevalence of face, nail, palm, and sole involve-
ment. In both baseline psoriasis severity groups, IXEQ2W demon-
strated superior efficacy to placebo and ETN at Week 12, and a
high level of efficacy was maintained with up to 156weeks of
IXEQ2W/IXEQ4W treatment. The safety profiles of the two psoriasis
severity groups were maintained over 3 years.
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